ex24-08232022_020845.htm

0001415889-22-008977.txt : 20220823 0001415889-22-008977.hdr.sgml : 20220823 20220823175356 ACCESSION NUMBER: 0001415889-22-008977 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220819 FILED AS OF DATE: 20220823 DATE AS OF CHANGE: 20220823 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Albers Jeffrey W. CENTRAL INDEX KEY: 0001638474 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 221188469 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORP. STREET 2: 215 FIRST STREET, SUITE 340/350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 form4-08232022_020845.xml X0306 4 2022-08-19 0001597264 Blueprint Medicines Corp BPMC 0001638474 Albers Jeffrey W. C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE MA 02139 true false false false Common Stock 2022-08-19 4 M 0 1590 15.01 A 184833 D Common Stock 2022-08-19 4 S 0 1590 70.02 D 183243 D Common Stock 2022-08-22 4 M 0 8410 15.01 A 191653 D Common Stock 2022-08-22 4 S 0 7748 70.47 D 183905 D Common Stock 2022-08-22 4 S 0 662 71.30 D 183243 D Stock Option (Right to Buy) 15.01 2022-08-19 4 M 0 1590 0 D 2026-02-03 Common Stock 1590 38410 D Stock Option (Right to Buy) 15.01 2022-08-22 4 M 0 8410 0 D 2026-02-03 Common Stock 8410 30000 D Effected pursuant to a trading plan adopted on January 11, 2022 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $70.00 to $70.06 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $70.00 to $70.98 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (4) The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $71.03 to $71.49 per share. This option was granted on February 3, 2016 and is fully vested as of the date hereof. /s/ Ariel Hurley, Attorney-in-Fact 2022-08-23 EX-24 2 ex24-08232022_020845.htm ex24-08232022_020845.htm

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Michael Landsittel, Ariel Hurley and Christopher Frankenfield, and each of them individually, and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

(1) Complete and execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer, director and/or ten percent (10%) shareholder of Blueprint Medicines Corporation, a Delaware corporation (the “Company”) any and all instruments, certificates and documents required to be executed on behalf of the undersigned as an individual or on behalf of the undersigned’s company or partnership, as the case may be, pursuant to Section 13 and Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or the rules and regulations thereunder;

(2) Do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such instruments, certificates or documents required to be filed pursuant to Sections 13 and 16 of the Exchange Act or the rules or regulations thereunder and timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) Take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act which is necessary, proper or desirable to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that any such attorney-in-fact, or any such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 13 or Section 16 of the Exchange Act or the rules or regulations thereunder. The undersigned hereby agrees to indemnify each attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to such attorney-in fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any instruments, certificates and documents pursuant to Section 13 and 16 of the Exchange Act or the rules or regulations thereunder with respect to the undersigned’s

holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of June 23, 2016.


	By:	/s/ Jeff W. Albers
	Name: Jeffrey W. Albers